Page 15 - ITPS-7-1

INNOSC Theranostics and
Pharmacological Sciences Liquid biopsy and digital PCR in cancer

13. Osherov N, Levitzki A, 1994, Epidermal-growth-factor- epidermal growth factor receptor monoclonal antibodies
dependent activation of the src-family kinases. Eur J in patients with metastatic colorectal cancer. Int J Oncol,
Biochem, 225: 1047–1053. 52: 1391–1400.
https://doi.org/10.1111/j.1432-1033.1994.1047b.x https://doi.org/10.3892/ijo.2018.4322
14. Laface C, Maselli FM, Santoro AN, et al., 2023, The 25. Gazdar AF, Minna JD, 2005, Inhibition of EGFR signaling:
resistance to EGFR-TKIs in non-small cell lung cancer: All mutations are not created equal. PLoS Med, 2: e377.
From molecular mechanisms to clinical application of new https://doi.org/10.1371/journal.pmed.0020377
therapeutic strategies. Pharmaceutics, 15: 1604.
26. Shigematsu H, Gazdar AF, 2006, Somatic mutations of
https://doi.org/10.3390/pharmaceutics15061604 epidermal growth factor receptor signaling pathway in lung
15. Zhang SS, Nagasaka M, 2021, Spotlight on sotorasib (AMG cancers. Int J Cancer, 118: 257–262.
510) for KRAS G12C positive non-small cell lung cancer. https://doi.org/10.1002/ijc.21496
Lung Cancer (Auckl), 12: 115–122.
27. Sanders HR, Albitar M, 2010, Somatic mutations of
https://doi.org/10.2147/lctt.s334623 signaling genes in non-small-cell lung cancer. Cancer Genet
16. Wee P, Wang Z, 2017, Epidermal growth factor receptor cell Cytogenet, 203: 7–15.
proliferation signaling pathways. Cancers (Basel), 9: 52. https://doi.org/10.1016/j.cancergencyto.2010.07.134
https://doi.org/10.3390/cancers9050052 28. Mésange P, Bouygues A, Ferrand N, et al., 2018,
17. Miyamoto Y, Suyama K, Baba H, 2017, Recent advances in Combinations of bevacizumab and erlotinib show activity
targeting the EGFR signaling pathway for the treatment of in colorectal cancer independent of RAS status. Clin Cancer
metastatic colorectal cancer. Int J Mol Sci, 18: 752. Res, 24: 2548–2558.
https://doi.org/10.3390/ijms18040752 https://doi.org/10.1158/1078-0432.ccr-17-3187
18. Ulz P, Belic J, Graf R, et al., 2016, Whole-genome plasma 29. Dankner M, Rose AA, Rajkumar S, et al., 2018,
sequencing reveals focal amplifications as a driving force in Classifying BRAF alterations in cancer: New rational
metastatic prostate cancer. Nat Commun, 7: 12008. therapeutic strategies for actionable mutations. Oncogene,
37: 3183–3199.
https://doi.org/10.1038/ncomms12008
https://doi.org/10.1038/s41388-018-0171-x
19. Yamaoka T, Ohba M, Ohmori T, 2017, Molecular-targeted
therapies for epidermal growth factor receptor and its 30. Maitre E, Bertrand P, Maingonnat C, et al., 2018, New
resistance mechanisms. Int J Mol Sci, 18: 2420. generation sequencing of targeted genes in the classical and
the variant form of hairy cell leukemia highlights mutations
https://doi.org/10.3390/ijms18112420 in epigenetic regulation genes. Oncotarget, 9: 28866–28876.
20. Sigismund S, Avanzato D, Lanzetti L, 2018, Emerging https://doi.org/10.18632/oncotarget.25601
functions of the EGFR in cancer. Mol Oncol, 12: 3–20.
31. Kamps R, Brandão RD, van den Bosch BJ, et al., 2017, Next-
https://doi.org/10.1002/1878-0261.12155 generation sequencing in oncology: Genetic diagnosis, risk
21. An L, Wang Y, Wu G, et al., 2023, Defining the sensitivity prediction and cancer classification. Int J Mol Sci, 18: 308.
landscape of EGFR variants to tyrosine kinase inhibitors. https://doi.org/10.3390/ijms18020308
Transl Res, 255: 14–25.
32. Lehmann-Che J, Poirot B, Boyer JC, et al., 2017, Cancer
https://doi.org/10.1016/j.trsl.2022.11.002 genomics guide clinical practice in personalized medicine.
22. Hasenahuer MA, Parisi G, Gautier M, et al., 2015, Twenty- Therapie, 72: 439–451.
one novel EGFR kinase domain variants in patients with https://doi.org/10.1016/j.therap.2016.09.015
nonsmall cell lung cancer. Ann Hum Genet, 79: 385–393.
33. Galetti M, Petronini PG, Fumarola C, et al., 2015, Effect of
https://doi.org/10.1111/ahg.12127 ABCG2/BCRP expression on efflux and uptake of gefitinib
23. Chen D, Li L, Zhang X, et al., 2018, FOLFOX plus anti- in NSCLC cell lines. PLoS One, 10: e0141795.
epidermal growth factor receptor (EGFR) monoclonal https://doi.org/10.1371/journal.pone.0141795
antibody (mAb) is an effective first-line treatment for
patients with RAS-wild left-sided metastatic colorectal 34. Shukla S, Patel A, Ambudkar SV, 2016, Mechanistic
cancer: A meta-analysis. Medicine (Baltimore), 97: e0097. and pharmacological insights into modulation of ABC
drug transporters by tyrosine kinase inhibitors. In:
https://doi.org/10.1097/MD.0000000000010097 George AM, editor. ABC Transporters-40 Years On.
Switzerland: Springer International Publishing, p227.
24. Matsuhashi N, Takahashi T, Matsui S, et al., 2018, A novel
therapeutic strategy of personalized medicine based on anti- 35. Vietsch EE, van Eijck CH, Wellstein A, 2015, Circulating

Volume 7 Issue 1 (2024) 9 https://doi.org/10.36922/itps.1227